Review



surface plasmon resonance spr biacore tm technology  (Biacore)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Biacore surface plasmon resonance spr biacore tm technology
    ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips <t>of</t> <t>Biacore</t> TM <t>SPR</t> technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.
    Surface Plasmon Resonance Spr Biacore Tm Technology, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/surface+plasmon+resonance+spr+biacore+tm+technology/plasmon+resonance+surface/pmc13024074-0-3-7
    Average 86 stars, based on 1 article reviews
    surface plasmon resonance spr biacore tm technology - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles"

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles

    Journal: Biosensors

    doi: 10.3390/bios16030174

    ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips of Biacore TM SPR technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.
    Figure Legend Snippet: ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips of Biacore TM SPR technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.

    Techniques Used: Bioassay, Activation Assay, Blocking Assay, Binding Assay

    Establishing a standardized SPR label-free bioassay for EV detection using rEVs. ( A ) The calibration curves using a series of rEV concentrations and anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies. The RUs were plotted as a function of the rEV concentrations (particles/mL). Simple linear regression was fitted using GraphPad prism software version 10.6. The LOD was calculated using (3.3*σ)/S = LOD, with σ being the standard deviation of the curve and S the slope of the curve. The error bars represent standard deviations (n = 3). ( B ) Stability and repeatability of the chip with different mouse antibodies. The capture levels are stable for at least 100 cycles. ( C ) Binding response from the three measurements of rEVs at a concentration of 1 × 10 9 particles/mL, illustrating interday precision.
    Figure Legend Snippet: Establishing a standardized SPR label-free bioassay for EV detection using rEVs. ( A ) The calibration curves using a series of rEV concentrations and anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies. The RUs were plotted as a function of the rEV concentrations (particles/mL). Simple linear regression was fitted using GraphPad prism software version 10.6. The LOD was calculated using (3.3*σ)/S = LOD, with σ being the standard deviation of the curve and S the slope of the curve. The error bars represent standard deviations (n = 3). ( B ) Stability and repeatability of the chip with different mouse antibodies. The capture levels are stable for at least 100 cycles. ( C ) Binding response from the three measurements of rEVs at a concentration of 1 × 10 9 particles/mL, illustrating interday precision.

    Techniques Used: Bioassay, Software, Standard Deviation, Binding Assay, Concentration Assay

    ( A – H ) SPR detection of tetraspanins CD9, CD63, CD81 and CXCR4 on purified EVs (SEC fraction 5). EVs were injected over C1 immunosensor functionalized with anti-mouse antibodies onto which anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies were captured (as depicted in ). Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). ( I ) Correlation of FCM data on cells and SPR data on EVs. FCM fold change data on cells is correlated with normalized data and is shown as logarithmic curve using Pearson’s correlation analysis, with r = 0.7960 ( p = 0.032) and 95% confidence interval (0.11–0.97).
    Figure Legend Snippet: ( A – H ) SPR detection of tetraspanins CD9, CD63, CD81 and CXCR4 on purified EVs (SEC fraction 5). EVs were injected over C1 immunosensor functionalized with anti-mouse antibodies onto which anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies were captured (as depicted in ). Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). ( I ) Correlation of FCM data on cells and SPR data on EVs. FCM fold change data on cells is correlated with normalized data and is shown as logarithmic curve using Pearson’s correlation analysis, with r = 0.7960 ( p = 0.032) and 95% confidence interval (0.11–0.97).

    Techniques Used: Purification, Injection, Binding Assay

    Detection of EVs in crude mixture using Biacore TM SPR technology. Normalized binding levels of HEK293 and HEK293.CXCR4 EVs spiked in DMEM cell medium supplemented with 10% ED-FBS when using anti- CD9, anti-CD63, anti-CD81 or anti-CXCR4 as capture antibodies. DMEM cell medium supplemented with 10% ED-FBS was used as control. Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). Statistical difference between groups was assessed by 1-way ANOVA with Tukey’s multiple comparison test (alfa = 0.05) (*: p = 0.0109, ***: p = 0.0004 and ****: p < 0.0001).
    Figure Legend Snippet: Detection of EVs in crude mixture using Biacore TM SPR technology. Normalized binding levels of HEK293 and HEK293.CXCR4 EVs spiked in DMEM cell medium supplemented with 10% ED-FBS when using anti- CD9, anti-CD63, anti-CD81 or anti-CXCR4 as capture antibodies. DMEM cell medium supplemented with 10% ED-FBS was used as control. Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). Statistical difference between groups was assessed by 1-way ANOVA with Tukey’s multiple comparison test (alfa = 0.05) (*: p = 0.0109, ***: p = 0.0004 and ****: p < 0.0001).

    Techniques Used: Binding Assay, Control, Comparison

    Related Articles

    SPR Assay:

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles
    Article Snippet: .. This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs). ..

    Diagnostic Assay:

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles
    Article Snippet: .. This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs). ..



    Similar Products

    surface plasmon resonance spr biacore tm technology  (Biacore)
    86
    Biacore surface plasmon resonance spr biacore tm technology
    ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips <t>of</t> <t>Biacore</t> TM <t>SPR</t> technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.
    Surface Plasmon Resonance Spr Biacore Tm Technology, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/surface+plasmon+resonance+spr+biacore+tm+technology/plasmon+resonance+surface/pmc13024074-0-3-7
    Average 86 stars, based on 1 article reviews
    surface plasmon resonance spr biacore tm technology - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips of Biacore TM SPR technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.

    Journal: Biosensors

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles

    doi: 10.3390/bios16030174

    Figure Lengend Snippet: ( A ) Schematic demonstration of label-free EV capture bioassay using C1 sensor chips of Biacore TM SPR technology. Created with BioRender.com (not drawn to scale). SPR sensorgram representing ( B ) activation of C1 sensor chip followed by RAM immobilization and blocking steps and ( C ) mouse monoclonal antibody capture followed by EV binding and regeneration step. Reference refers to sample without addition of antibodies. Asterisk indicates time point at which amount of bound EVs was measured.

    Article Snippet: This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs).

    Techniques: Bioassay, Activation Assay, Blocking Assay, Binding Assay

    Establishing a standardized SPR label-free bioassay for EV detection using rEVs. ( A ) The calibration curves using a series of rEV concentrations and anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies. The RUs were plotted as a function of the rEV concentrations (particles/mL). Simple linear regression was fitted using GraphPad prism software version 10.6. The LOD was calculated using (3.3*σ)/S = LOD, with σ being the standard deviation of the curve and S the slope of the curve. The error bars represent standard deviations (n = 3). ( B ) Stability and repeatability of the chip with different mouse antibodies. The capture levels are stable for at least 100 cycles. ( C ) Binding response from the three measurements of rEVs at a concentration of 1 × 10 9 particles/mL, illustrating interday precision.

    Journal: Biosensors

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles

    doi: 10.3390/bios16030174

    Figure Lengend Snippet: Establishing a standardized SPR label-free bioassay for EV detection using rEVs. ( A ) The calibration curves using a series of rEV concentrations and anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies. The RUs were plotted as a function of the rEV concentrations (particles/mL). Simple linear regression was fitted using GraphPad prism software version 10.6. The LOD was calculated using (3.3*σ)/S = LOD, with σ being the standard deviation of the curve and S the slope of the curve. The error bars represent standard deviations (n = 3). ( B ) Stability and repeatability of the chip with different mouse antibodies. The capture levels are stable for at least 100 cycles. ( C ) Binding response from the three measurements of rEVs at a concentration of 1 × 10 9 particles/mL, illustrating interday precision.

    Article Snippet: This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs).

    Techniques: Bioassay, Software, Standard Deviation, Binding Assay, Concentration Assay

    ( A – H ) SPR detection of tetraspanins CD9, CD63, CD81 and CXCR4 on purified EVs (SEC fraction 5). EVs were injected over C1 immunosensor functionalized with anti-mouse antibodies onto which anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies were captured (as depicted in ). Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). ( I ) Correlation of FCM data on cells and SPR data on EVs. FCM fold change data on cells is correlated with normalized data and is shown as logarithmic curve using Pearson’s correlation analysis, with r = 0.7960 ( p = 0.032) and 95% confidence interval (0.11–0.97).

    Journal: Biosensors

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles

    doi: 10.3390/bios16030174

    Figure Lengend Snippet: ( A – H ) SPR detection of tetraspanins CD9, CD63, CD81 and CXCR4 on purified EVs (SEC fraction 5). EVs were injected over C1 immunosensor functionalized with anti-mouse antibodies onto which anti-CD9, anti-CD63, anti-CD81 and anti-CXCR4 antibodies were captured (as depicted in ). Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). ( I ) Correlation of FCM data on cells and SPR data on EVs. FCM fold change data on cells is correlated with normalized data and is shown as logarithmic curve using Pearson’s correlation analysis, with r = 0.7960 ( p = 0.032) and 95% confidence interval (0.11–0.97).

    Article Snippet: This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs).

    Techniques: Purification, Injection, Binding Assay

    Detection of EVs in crude mixture using Biacore TM SPR technology. Normalized binding levels of HEK293 and HEK293.CXCR4 EVs spiked in DMEM cell medium supplemented with 10% ED-FBS when using anti- CD9, anti-CD63, anti-CD81 or anti-CXCR4 as capture antibodies. DMEM cell medium supplemented with 10% ED-FBS was used as control. Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). Statistical difference between groups was assessed by 1-way ANOVA with Tukey’s multiple comparison test (alfa = 0.05) (*: p = 0.0109, ***: p = 0.0004 and ****: p < 0.0001).

    Journal: Biosensors

    Article Title: Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles

    doi: 10.3390/bios16030174

    Figure Lengend Snippet: Detection of EVs in crude mixture using Biacore TM SPR technology. Normalized binding levels of HEK293 and HEK293.CXCR4 EVs spiked in DMEM cell medium supplemented with 10% ED-FBS when using anti- CD9, anti-CD63, anti-CD81 or anti-CXCR4 as capture antibodies. DMEM cell medium supplemented with 10% ED-FBS was used as control. Binding levels (RU) were normalized based on particle number, as explained in . Error bars represent standard deviations (n = 3). Statistical difference between groups was assessed by 1-way ANOVA with Tukey’s multiple comparison test (alfa = 0.05) (*: p = 0.0109, ***: p = 0.0004 and ****: p < 0.0001).

    Article Snippet: This study leverages surface plasmon resonance (SPR) Biacore TM technology to unveil the diagnostic potential of detecting CXCR4 on extracellular vesicles (EVs).

    Techniques: Binding Assay, Control, Comparison